Cabozantinib is a c-Met inhibitor that is currently FDA approved for the treatment of patients with advanced renal cell carcinoma (RCC).
| SparkCures ID | 69 |
|---|---|
| Developed By | Exelixis |
| Generic Name | Cabozantinib |
| Additional Names | Cabometyx |
| Treatment Classifications |
|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.